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The Netherlands Society of Cardiology (NVvC) and the
European Society of Cardiology have assumed respon-
sibility for the quality of care in the Netherlands and in
Europe. To this end, the societies organise congresses
and publish journals to promote exchange of informa-
tion on research and developments in cardiology. The
societies develop guidelines for prevention, diagnosis
and management of cardiovascular disease and they
promote education programmes. Surveys and registries
provide information on the actual practice of cardiology,
to assess whether the guidelines are followed in clinical
practice, to identify areas where improvements can be
made and to verify whether the guidelines, and the
clinical trials on which these are often based, really
address the patients which we see in our practices
(Fig. 1). Unfortunately few systematic registries of pa-
tient care are operational in our country. Therefore other
sources of information should be used to gain insight
into the practice of cardiology and cardiovascular med-
icine. A clinical trial can be such a source, since patient
characteristics, treatment modalities and outcome are
carefully recorded.
The report by Soedamah-Muthu and others from the
Alpha-Omega trial [1] is a good example and provides
information on the characteristics and the care of patients
after myocardial infarction in the Netherlands. The Alpha-
Omega trial investigated whether a diet with n-3 fatty acids
would reduce the rate of cardiovascular events among
patients after a myocardial infarction [2]. The authors should
be complimented on their unique, well designed and
conducted trial with different types of margarines supple-
mented with two different n-3 fatty acids. Although previous
cohort studies indicated a protective effect of n-3 fatty acids,
no such effect was found in the trial of patients who received
state-of-the-art antihypertensive, antithrombotic, and lipid-
modifying therapy.
The Alpha-Omega trial enrolled 4835 patients with a
history of myocardial infarction from 32 hospitals between
2002 and 2006. Their mean age was 69 years and 78% were
men. Overall the patients were treated intensively: in 2006,
98% received antithrombotic drugs, 87% a statin (and 3% or
more other lipid-modifying drugs), 75% a beta blocker, and
59% an ACE inhibitor or angiotensin II receptor blocker.
Lipid levels and blood pressure were reasonably controlled,
but no information was provided on the level of control of
diabetes in the 22% of patients with this disease. As in other
surveys conducted in the same period (Fig. 2), the use of
medication increased appropriately over the years 2002 –
2006. The authors compare these findings with the
EUROASPIRE-III survey conducted in 2007 [3]. The
patients in the Netherlands were older, with overall lower
levels of obesity, hypercholesterolaemia, hypertension and
diabetes. The patients received similar levels of antithrom-
botic and lipid-modifying drugs, but fewer beta blockers and
ACE inhibitors were prescribed in the Netherlands. In both
the EUROASPIRE survey and the Alpha-Omega trials high
prevalences of smoking, obesity and diabetes were ob-
served, which calls for action, although such lifestyle is
difficult to change.
From this report different lessons can be drawn. We
may be complacent, since overall cardiologists in the
Netherlands who participated in the trial did treat their
patients according to the guidelines in 2002–2006. The
report confirms that too many patients continue their
‘bad habits’ such as smoking and too rich a diet leading
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gists do about it? Habits are not easy to change’.W e
may question the relatively low prescription rates of
beta blockers and ACE inhibitors and the NVvC and
the Netherlands Institute for Continuing Cardiovascular
Education (CVOI) may plan to discuss the guidelines and the
underlying clinical trials again at a next congress and educa-
tionprogramme.Wemayquestiontheuseofother,non-statin,
lipid-modifying drugs inatleast 3%ofthe patientssince these
drugs may reduce the LDL-cholesterol level, but there are no
consistent data that these drugs have a favourable impact on
survival or reduction of cardiovascular events. The outcomes
of the ongoing IMPROVE-IT trial to assess the value of
ezetimibe in secondary prevention are eagerly awaited. In-
deed, we might sit back and be reassured that in our practice
we need just a bit more attention to further improve our
secondary prevention measures.
However, to my regret, no data on the 32 individual
practices are presented in the report. To assess the quality
of our practices we cannot hide behind overall data from our
country, even if one third of the hospitals in the Netherlands
have provided these data. We need to compare the actual
data from our own practice, from our own hospital, with
others to identify areas for our own improvement. We need
actual data from 2011 and 2012 and should not be satisfied
with a review of data collected several years ago because
practices change, as illustrated again in Fig. 2 and in the
report by Soedamah-Muthu and others [1]. I do believe that
most cardiologists in the Netherlands provide a good ser-
vice, but I have no access to data on individual practices to
verify this belief. Together we fail to collect and provide
such data on patient care, on the use of diagnostic resources
and on specific therapeutic procedures in interventional
cardiology and clinical electrophysiology. What are the out-
comes of these procedures in different hospitals? Which
complications do occur and how frequently? Insight into
such data, in actual data from 2011 and 2012, is required
to further improve the quality of our care.
A registry of all procedures, outcome and complica-
tions is a requirement for licences for interventional
cardiology and other procedures. The National Cardio-
vascular Data Registry (NCDR) has been created for this
purpose. Registries for pacemaker and ICD implantation,
for percutaneous coronary interventions and for percuta-
neous aortic valve implantation have been developed, but
I understand that data collection is slow, that existing
registries in different hospitals are not fully consistent
and that no agreement has been reached on the type of
reports which professionals and the public may expect.
Yet, agreement on the content of many registries was
reached at the European level several years ago [4] and
a first report was published from the hospitals participating in
the Euro-Heart Survey / Zorgprogramma Nederlandse
Hartstichting [5]. I look forward to similar reports with up-
to-date information from all hospitals in the Netherlands.
Some othercountries havebeen moresuccessful in this matter,
for example Sweden with the ongoing RIKS-HIA registries
which can be found on the internet with many details on the
performance of all Swedish hospitals [6]. The NVvC should
ensurethattogetherwewillcollectandprovidetheinformation
which is required to benchmark our practices. We should
overcome the hurdles and ‘cold feet’ which have blocked
progress in this field. The report from the Alpha-Omega trial
confirmsthatwe doreasonablywell,butwecandoevenbetter
if we all participate in a proper benchmarking system.
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Fig. 2 Summary of prescription of preventive therapy in different sur-
veys by the European Society of Cardiology. EA-I, EA-II, EA-III repre-
sent EuroAspire I, II, III respectively, ACS-I and ACS-II represent
surveys of Acute Coronary Syndromes, CR 0 survey of coronary revas-
cularisation, AP 0 survey of stable angina pectoris, DM 0 survey of
diabetes and the heart, PCI 0 survey of percutaneous coronary interven-
tion. Adapted from the ESC report ‘Cardiovascular diseases in Europe
2004’ by adding data from subsequent surveys. Reproduced from
Simoons: A half ounce of prevention, Eur Heart J. 2011;32,2098–9
Fig. 1 Quality development and quality assurance programmes
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